Alzheimer’s disease is caused by the accumulation in certain areas of the brain of insoluble amyloid protein plaques, causing dementia, followed by steady mental deterioration.
To prevent or delay the onset of the disease are investigated vaccines that mimic the amyloid peptide production, by stimulating the immune system making antibodies, which are safe, minimizing the possible adverse effects.
No clinical trials or economic evaluation studies have been located that reveal results of safety, efficacy and cost of this new technology.
There are numerous studies in experimental stage, investigating molecules for the creation of possible prophylactic measures for this type of dementia.